Atomic AI

AI-driven RNA drug discovery, with atomic precision.

Freemium Healthcare & Life Sciences

About Atomic AI

Atomic AI is an early-stage biotechnology company based in South San Francisco, California, founded in 2020. The company focuses on RNA-targeted drug discovery by integrating artificial intelligence with structural biology. Their mission is to develop new therapeutic strategies for diseases that have been difficult to treat by targeting RNA structures.

The company utilizes a proprietary research and development platform that combines deep learning algorithms with in-house wet-lab assays. This approach enables the discovery of novel structural targets and the optimization of RNA medicines. Atomic AI is currently developing RNA-targeting small molecules aimed at treating neurodegenerative and infectious diseases, which are in the discovery phase. The team consists of machine learning researchers and experimental biologists, guided by experienced scientific advisers and investors.
No screenshot available